Switzerland Roche InterMune

Switzerland Roche InterMune

Swiss pharmaceutical company Roche says it will buy InterMune, Inc., a California-based developer of treatments for lung diseases, in a deal worth $8.3 billion. Roche said Sunday the companies have reached an agreement under which Roche will acquire InterMune in an all-cash transaction. (AP Photo/Keystone/Urs Flueeler, File)

Go back to reading “Roche to buy biotech firm InterMune for $8.3 billion”

Copyright 2017 by The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

LTW Partners

Techwire Inside Partners